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Abstract Metabotropic pyrimidine and purine nucleotide
receptors (P2Y receptors) belong to the superfamily of G
protein-coupled receptors (GPCR). They are distinguish-
able from adenosine receptors (P1) as they bind adenine
and/or uracil nucleotide triphosphates or diphosphates
depending on the subtype. Over the past decade, P2Y
receptors have been cloned from a variety of tissues and
species, and as many as eight functional subtypes have
been characterized. Most recently, several members of the
P2Y12-like receptor group, which includes the clopidogrel-
sensitive ADP receptor P2Y12, have been deorphanized.
The P2Y12-like receptor group comprises several structur-
ally related GPCR which, however, display heterogeneous
agonist specificity including nucleotides, their derivatives,
and lipids. Besides the established function of P2Y12 in
platelet activation, expression in macrophages, neuronal
and glial cells as well as recent results from functional
studies implicate that several members of this group may
have specific functions in neurotransmission, inflammation,
chemotaxis, and response to tissue injury. This review
focuses specifically on the structure-function relation and
shortly summarizes some aspects of the physiological
relevance of P2Y12-like receptor members.
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Introduction
Most cellular effects of nucleotides are mediated through
two main families of specific cell surface receptors, the
ionotropic P2X and metabotropic P2Y nucleotide receptors.
The metabotropic receptors belong to the superfamily of G
protein-coupled receptors (GPCR). The GPCR superfamily
comprises at least five structurally distinct families/sub-
families (GRAFS classification) which share little sequence
homology among each other [1]. The rhodopsin-like
receptors (also called family A or 1) form the largest
family in vertebrates. Eight different mammalian P2Y
(P2Y1, 2, 4, 6, 11–14) receptor subtypes, all belonging to the
rhodopsin-like receptors (family A), have been identified
a n dp r o v e nt of u n c t i o na sr e c e ptors for extracellular
nucleotides so far [2]. Based on their preferential agonists,
P2Y receptors have been subclassified into adenine
nucleotide-activated (P2Y1,P 2 Y 11,P 2 Y 12,P 2 Y 13), pyrimi-
dine nucleotide-activated (P2Y4,P 2 Y 6), ATP/UTP-activated
(P2Y2), and UDP-sugar-activated (P2Y14)r e c e p t o r s .M o s t
structural and functional studies were performed with the
classic P2Y receptors P2Y1 and P2Y2 [3]. However, in
comparison to other GPCR, large-scale structure/function
data are rare, mainly due to difficulties in finding suitable
P2Y-free heterologous expression systems [4]. Pharmaco-
logical characterization on both native and recombinant
P2Y receptors is further hampered by the release of
endogenous nucleotides and the hydrolysis or conversion
of exogenous and endogenous nucleotides by ectoenzymes
(for review see [5]). ATP and AMP are metabolized by cell
surface enzymes, the ecto-NTPDase 1 (nucleoside triphos-
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lizes ATP to AMP) and the 5′-ectonucleotidase (CD73,
metabolizes AMP to adenosine). In addition, a nucleoside
diphosphokinase catalyzes the transfer of the gamma
phosphate of nucleoside triphosphates to nucleoside
diphosphates. For example, in the presence of ATP,
nucleoside diphosphokinase catalyzes the conversion of
UDP to UTP. These specific problems may have contrib-
uted to many false and controversial declarations of P2Y
receptors being activated by nucleotides [6–9]. Recent
success in expressing GPCR in yeast, which is discussed
below, may circumvent these problems and may engage
structure-function-relation studies.
Although in-depth phylogenetic analysis of GPCR
groups indicates clustering of P2Y receptors, when com-
pared with other GPCR of family A [1, 10], the adenine
nucleotide-activated P2Y1 and P2Y12, for example, display
only minor structural relation at the protein level. Phyloge-
netic analysis even revealed that nucleotide specificity e.g.
for ADP evolved independently in P2Y1 and P2Y12.S ow e
suggest that grouping of P2Y receptors should be per-
formed on phylogenetic aspects rather than on ligand
specificity.
Based on their amino acid sequences P2Y receptors can
be subdivided into at least two groups (Fig. 1). One
comprises P2Y1, 2, 4, 6, 11, and the second group contains
P2Y12–14. Additionally, several other structurally related
GPCR, such as CysLT1R, GPR91, GPR99, and GPR34,
cluster into both groups (Fig. 1). These receptors are
activated by structurally different ligands such as leuko-
trienes, organic acids, and phospholipids. Probably because
of their structural relation several P2Y receptors display
agonist promiscuity. It was shown that not only ADP but
also leukotriene E4 (LTE4) activates P2Y12 at nanomolar
concentrations [11]. Cysteinyl leukotriene receptors
(CysLT1R and CysLT2R) have been described to be
activated by UDP in addition to activation by cysteinyl
leukotrienes [12, 13]. Further, there is evidence that
CysLT1R antagonists, such as pranlukast and montelukast,
inhibit activation of P2Y1 and P2Y6 by 2MeS-ADP (2-
methylthio-ADP) and UDP, respectively [14]. Although
P2Y12 and cysteinyl leukotriene receptors are clinically
used targets for prevention of thrombocyte aggregation
(clopidogrel) and treatment of asthma (montelukast),
respectively, the structural basis and (patho)physiological
relevance of dual/multiple agonist specificity is obscure.
Close structural relations between P2Y and other non-
nucleotide receptors as well as the mentioned examples of
ligand promiscuity indicate that nucleotides are probably
only one of many natural agonists on the genuine P2Y
receptors.
Structural evolution of P2Y12-like GPCR
Discovery and deorphanization of group members
The ADP-(P2Y12)-like receptor group is the most recently
identified P2Y receptor group and includes P2Y12, P2Y13,
and P2Y14 (see Fig. 1, Table 1). Based on high structural
Fig. 1 Phylogenetic relation of
human P2Y receptors. To eval-
uate the structural relation of
P2Y receptors and related
GPCR, amino acid sequences of
human orthologs were aligned
and phylogenetic relations were
estimated using CLUSTAL W.
The derived tree was essentially
identical to former analysis [2,
10]. The P2Y12-like receptors
cluster into a group (framed)
that is distinct from other nu-
cleotide receptors such as P2Y1
and P2Y2
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and several orphan GPCR (GPR34-like, GPR82, GPR87,
GPR171) are considered members of the structural P2Y12-
like receptor group (3,11). Most members of this group
were deorphanized by the so-called reverse pharmacology
approach. The orphan receptors predicted from sequence
data are now often used to ascertain the ligands by testing
them on tissue extracts and subsequent fractionation or on
huge libraries of bioactive compounds, whereas, tradition-
ally, the bioactive ligand was used to identify the receptor
(classic approach).
As the first member of the P2Y12-like receptor group
P2Y14 (synonyms KIAA0001, GPR105, VTR 15–20) was
identified [15, 16] and then deorphanized in the year 2000
[17]. UDP-glucose was found to activate P2Y14 by
screening multiple receptors, each expressed in individual
yeast strains, against a large library of over 700 known and
putative natural GPCR agonists.
In 2001, P2Y12 (initially named SP1999) was discovered
and identified as the platelet clopidogrel-sensitive ADP
receptor by a number of groups [18–21]. The P2Y12 was
deorphanized with both the classic and the reverse
pharmacology approaches. Hollopeter et al. used subfrac-
tionated transcripts from platelets and isolated the cRNA
(complementary RNA, encoding e.g. the P2Y12 receptor)
which mediated ADP-induced increases in K
+ current after
injection into Xenopus oocytes [19]. In contrast, fraction-
ated rat spinal cord extracts were assayed for Ca
2+
mobilization in cells transiently transfected with P2Y12
and chimeric Gα subunit [21]. Almost in parallel, ADP was
shown to be an agonist for P2Y13 (former GPR86), a very
close structural neighbor of P2Y12 [22–24]. 2MeS-ADP is
the most potent agonist at P2Y12 followed by ADP,
adenosine 5′-O-2-thiodiphosphate, and ATP. (N)-methano-
carba-2-methylthio-ADP, a highly potent agonist at P2Y1,
exhibited no and only minor agonist activity at P2Y12 and
P2Y13, respectively [25].
Based on structural relations GPR34 [26, 27], GPR82
[28], GPR87 [29], and GPR171 (synonym H963) [30] also
belong to the P2Y12-like group (see Fig. 1). Except for
GPR34, which was recently identified as a receptor for
lyso-phosphatidylserine [31] by a reverse pharmacology
approach, all the other P2Y12-like receptors are still orphan
GPCR.
The evolutionary origins
Based on structural similarities P2Y12-like receptors cluster
into a group distinct from other P2Y receptors (see Figs. 1
and 2). This P2Y12-like receptor group can be subdivided
into two subgroups. One subgroup encompasses P2Y12,
P2Y13, P2Y14, GPR87, and GPR171, the other subgroup
GPR34, GPR34-like, and GPR82 (Fig. 2). This may
suggest that both subgroups evolved from gene duplications
starting from two related members. The grouping is further
supported by shared genomic localization. Chromosomal
clustering in the human genome is found for P2Y12,P 2 Y 13,
P2Y14, GPR87, and GPR171 at 3q24-3q25 as well as for
GPR34 and GPR82 at Xp11.4. This clustering is evolu-
tionary well preserved. In the zebrafish genome P2Y12,
Table 1 Members of the P2Y12-like receptor family
Receptor G protein
coupling
Natural agonist Tissue expression
P2Y12 Gi ADP, CysLT-E4, phosphoribosyl
pyrophosphate
Platelets, brain (glia) [19]
P2Y13 Gi ADP, diadenosine triphosphate Spleen and adult brain, lower expression in placenta, lung, liver, spinal cord,
thymus, spleen, small intestine, uterus, stomach, testis, fetal brain, adrenal
gland, lymph node, bone marrow, peripheral blood mononuclear cells,
leukocytes [22, 45]
P2Y14 Gi UDP-glucose, UDP-galactose, UDP-
glucuronic acid, UDP-N-
acetylglucosamine
Brain (astrocytes, glia), placenta, adipose tissue, stomach, intestine, spleen,
lung (epithelium), heart [15, 16, 71]
GPR87 Gi n.k Placenta, thymus, small intestine, colon, prostate, uterus, testis, peripheral
blood leukocytes [28, 29]
GPR171 n.k n.k n.k
GPR34 Gi lyso-phosphatidylserine Brain, glia cells, mast cells, spleen, heart, kidney, liver [27, 31, 34, 72]
GPR82 n.k n.k Testes, epididymis (unpublished own results)
Based on phylogenetic analyses and structural similarities the seven GPCR clusters in a group which is distinct from other P2Y receptors (see Fig.
1). Although they share structural features it appears from current studies that not all members are receptors for nucleotides. The table lists the
currently known receptor agonists, the receptor’s G protein specificity and expression pattern
n.k not known
Purinergic Signalling (2007) 3:255–268 257P2Y14/GPR87, and GPR171 cluster at chromosome 15 and
GPR34 type 2 and GPR82 are tandemly arranged at
chromosome 9. Gene clustering is not only found for
vertebrate P2Y12-like receptors but also for several other
GPCR genes. Multiple copies of related GPCR genes, such
as the human protease-activated receptors on 5q13, trace
amine-associated receptors (TAAR, human 6q23.2), and
CC-chemokine receptors (human 3p21.3), are the result of
intrachromosomal gene duplications. The most impressive
example is found in odorant receptors, where in humans,
chromosome 11 contains nearly half of the odorant receptor
repertoire, including a single cluster of more than 100
odorant receptors [32]. Gene amplification can be viewed
as a dynamic and reversible regulatory mechanism that
facilitates adaptation to variable environments. Clustered
genes may confer selective benefits via their ability to be
co-regulated and co-amplified. Indeed, even transcripts
encoding a fusion protein of GPR34 and GPR82 have been
Fig. 2 Evolutionary origin of
P2Y12-like receptors. To sub-
classify and evaluate the phylo-
genetic relations between the
P2Y12-like receptors, the amino
acid sequences of orthologs
from one species of each verte-
brate class (if available) were
aligned using CLUSTAL W
(identity matrices) and a phylo-
genetic tree was constructed
(1,000 iterations). Bootstrap
values >600 were considered as
significant to support a new
branch
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ical relevance of P2Y12-like receptor clustering in respect to
transcriptional activity at their respective genomic loci, co-
regulation, and transcript diversity need to be determined in
the future.
Since P2Y12,P 2 Y 14/GPR87, GPR34, and GPR34-like
are all found in sharks (Mustelus manazo, Carcharodon
carcharias) and chimeras (Callorhinchus milii) one can
assume that P2Y12-like receptors arose more than 450
million years (Myr) ago, before cartilaginous and bony fish
split. Our own polymerase chain reaction (PCR) amplifica-
tion attempts as well as the ongoing lamprey (Petromyzon
marina) and sea urchin (Strongylocentrotus purpuratus)
genome projects revealed no P2Y12-like sequences yet,
suggesting their origin in the very early Gnathostomata or,
less likely, a loss in agnate and all non-vertebrates.
Gene duplication can be a primary source of the genetic
material from which genes with new functions evolve. One
copy of a duplicated gene may become mutated and acquire
unique functionality without risking the fitness of the
organism ensured by the homolog. On the other hand, if
not advantageous, continuous accumulation of mutations
(neutral drift) will eliminate one of the genes, a process
named pseudogenization. In fish genomes, there is only one
respective ortholog with relation to P2Y12/P2Y13 and to
GPR87/P2Y14.I nt h ec a s eo fP 2 Y 12/P2Y13 the fish
ortholog is more closely related to P2Y12 implicating that
P2Y13 evolved later in tetrapod evolution probably by
P2Y12 duplication. However, one cannot rule out that the
gene was eliminated in the common ancestor of sharks and
bony fishes. The evolutionary mechanism of P2Y14 and
GPR87 evolvement remains unsolved since their structural
relation to the fish orthologs is similar. The absence of
P2Y14 in the African craw frog (Xenopus) genome but the
presence of ortholog sequences in all other sequenced
tetrapod genomes does not necessarily implicate that P2Y14
derived from GPR87 in early tetrapod evolution. Again,
P2Y14 gene loss in amphibians must be considered.
Orthologs of GPR34, GPR87/P2Y14, and P2Y12 are
found in all tetrapods and bony and cartilaginous fishes
investigated so far. However, not all members of the P2Y12-
like group appear to be present in all vertebrate classes.
GPR82 has an ortholog in zebrafish but is not yet found in
the genomes of pufferfishes and the lizard (Anolis caro-
linensis) genome. Although GPR171 is found in reptiles,
birds, mammals, zebrafish, and chimera it appears to be
absent in African craw frog, stickleback, and pufferfishes.
This may implicate specific functions of some P2Y12-like
receptors which are less important in some species or are
compensated by other receptors and mechanisms.
Signatures of gene inactivation (pseudogenization) are
rarely found for members of the P2Y12-like group.
Following gene duplication in the common ancestor of
evolutionary basic fishes, like eels and carps [33], pseudo-
genization of one GPR34 subtype was identified in a
salmon species (Keta salmon) (own unpublished results).
The GPR34-like receptor is an evolutionary old P2Y12-like
receptor being present in cartilaginous and bony fishes,
amphibians, and birds but not in mammals (Fig. 2).
Sequences with residual relation to the GPR34-like receptor
are found in the platypus genome but it is most likely a
pseudogene.
Genomic organization of P2Y12-like receptors
Comparison of transcript and genomic sequences provides
information on intron/exon structure of a GPCR gene.
Since the gain or loss of spliceosomal introns are unique
events in evolution, they can serve as markers for
phylogenetic analysis. Further, such analyses may reveal
splice variants and may be informative about the promoter
structure and gene regulation. Introns are the basis of
alternative splicing, exon skipping, and RNA editing events
and, therefore, can contribute to receptor diversity at a
supragenomic level.
Most coding regions of human P2Y12-like receptors do
not contain introns (Table 2). One exception is GPR87
where the genomic sequence encoding the receptor’sN
terminus is interrupted by an intron in mammalian and
avian orthologs. Another intron which is rarely removed
(cryptic intron) has been identified in the N terminus-
encoding sequence of GPR34 [34].
The genomic organization of the individual P2Y12-like
receptor genes is not well conserved during vertebrate
evolution (see Table 2). For example, the P2Y12 gene
gained an intron in bony fish evolution disrupting the open
reading frame of the transmembrane domain 2 (TMD2)-
encoding part. Similarly, one of the two GPR34 paralog
genes acquired an intron in the more recent bony fish
evolution [33]. The two long-standing alternative explan-
ations for the origin of introns, the intron-early theory and
intron-late theory, remain a matter of continuous debate not
only for GPCR [35]. The intron-early theory suggests that
introns are extremely ancient characteristics of genes and
that early genes were created through the intron-mediated
shuffling of exons. However, numerous gene and genome
comparison studies provided evidence that at least some
introns are more recently acquired (intron-late theory). The
P2Y12-like receptor group is, therefore, a nice example
where introns were acquired in the coding region in some
species during more recent evolution.
In contrast to the coding region, the 5′ region of most
members of the P2Y12-like receptor group displays a
distinct intron/exon organization with sometimes multiple
transcription starts. Also, the gene sizes strongly differ
between the individual and even closely related receptors.
Purinergic Signalling (2007) 3:255–268 259Table 2 Genomic organization of P2Y12-like GPCR. n.a. not analyzed because of lack of mRNA information
Member Number of introns in the 5′ non-coding
region
Number of introns in the coding region Approx. size of genomic region
a
P2Y12
Human 1–2 − 47 kbp (2 different transcript starts)
Mouse 4 − 46.5 kbp
Chicken n.a. −
b n.a. (>1 kbp)
African clawed
frog
− 1 (N terminus) 4 kbp
Zebrafish n.a. −
b n.a. (>1 kbp)
Stickleback 1 1 (TMD2) 2 kbp
Pufferfish n.a. 1 (TMD2) >2 kbp
P2Y13
Human − 1 (rare transcript, N terminus, NM_176894) 3.2 kp (2 different transcript starts)
Mouse 1 − 3 kbp
Chicken n.a. −
b n.a. (>1 kbp)
African clawed
frog
− 1 (N terminus) 14–19 kbp
P2Y14
Human 2 − 66 kbp (2 different transcript starts)
Mouse 1–2 − 16 kbp
Chicken n.a. −
b n.a. (>1 kbp)
GPR87
Human 1 1 (N terminus) 22.7 kbp
Mouse 1 1 (N terminus) 16 kbp
Chicken 2 1 (N terminus) 9.5 kbp
African clawed
frog
n.a. −
b n.a. (>1 kbp)
P2Y14/GPR87
Zebrafish n.a. −
b n.a. (>1 kbp)
Pufferfish n.a. −
b n.a. (>1 kbp)
GPR171
Human 2 − 5 kbp
Mouse 1 − 4.5 kbp
Chicken 1 − 2.3 kbp
Zebrafish n.a. −
b n.a. (>1 kbp)
GPR82
Human 2 − 4 kbp
Mouse 2–3 − 6 kbp
Chicken n.a. −
b n.a. (>1 kbp)
African clawed
frog
n.a. −
b n.a. (>1 kbp)
Zebrafish n.a. −
b n.a. (>1 kbp)
GPR34
Human 3–4 1 cryptic (N terminus) 8.2 kbp
Mouse 3–4 − 9.1 kbp
Chicken 1 − 2.5 kbp
African clawed
frog
2 − 5.2 kbp
Zebrafish
Type 1 1 − 7.3 kbp
Type 2 −− 1.2 kbp
Pufferfish n.a. −
b n.a. (>1 kbp)
Except for GPR87, human P2Y12-like receptor members contain no intron in the coding region. However, this intronless gene structure is not well
preserved in all vertebrates. The table summarizes the number of introns within the 5′ and coding region of selected vertebrate genes and estimates
the size of the gene
aBased on the 5′ longest transcript
bComplete open reading frame within the genomic sequence but intron within the very N terminus cannot be ruled out because of lack of mRNA
information
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receptors have not been found yet. Large and complex
organized 5′ non-coding regions of a gene may provide the
basis for multiple promoter regions, cis-acting elements,
and a variable 5′ UTR of the mRNA. Alternative structures
of the 5′ UTR can contribute to expression regulation and
alternative translation start points. For example, 5′ UTRs
often contain small open reading frames (ORF) which can
be translated via leaky scanning at the ribosome. Such
leaky scanning can reduce translation of the downstream
main ORF as shown for several genes including GPCR
[36, 37].
It is of interest to note that both genes, GPR34 and
GPR82, are located in antisense orientation within a large
intron of the CASK gene. This position is conserved during
vertebrate evolution. The CASK gene encodes a calcium/
calmodulin-dependent serine protein kinase that is a
member of the membrane-associated guanylate kinase
(MAGUK) protein family. Since GPR34 and GPR82
transcripts are antisense orientated to CASK one can
speculate that transcripts may regulate expression of CASK
or vice versa. Such hypotheses will be addressed in
receptor-deficient mouse models (see below) in the future.
Key residues defining the individual member
Many attempts have been made to identify structural
signatures which are helpful in annotation and grouping
of P2Y receptors. On the basis of available sequence data
for validated P2Y receptors, key residues were extracted to
define P2Y12-like and P2Y1-like receptor groups [11, 38,
39]. In recent studies, we have shown for several GPCR
that a significant number of orthologs is required for
identification of functional motifs and key residues [33,
40–42]. By mining public databases and by amplifying and
sequencing P2Y12-like orthologs we have acquired large
sets of sequences of P2Y12 (74 orthologs), P2Y13 (31
orthologs), P2Y14 (38 orthologs), GPR87 (51 orthologs),
GPR171 (41 orthologs), GPR82 (34 orthologs), and GPR34
(133 orthologs) to determine structural conservation of the
P2Y12_                        MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIR-SKSNFIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVI----FYFTMYI
P2Y13_                          MNTTVMQGFNRSERCPRDTRIVQLVFPALYTVVFLTGILLNTLALWVFVHIP-SSSTFIIYLKNTLVADLIMTLMLPFKILSDSHLAPWQLRAFVCRFSSVI----FYETMYV
P2Y14_                           MINSTSTQPPDESCSQNLLITQQIIPVLYCMVFIAGILLNGVSGWIFFYVP-SSKSFIIYLKNIVIADFVMSLTFPFKILGDSGLGPWQLNVFVCRVSAVL----FYVNMYV
GPR87_       MGFNLTLAKLPNNELHGQESHNSGNRSDGPGKNTTLHNEFDTIVLPVLYLIIFVASILLNGLAVWIFFHIR-NKTSFIFYLKNIVVADLIMTLTFPFRIVHDAGFGPWYFKFILCRYTSVL----FYANMYT
GPR171_              MTNSSFFCPVYKDLEPFTYFFYLVFLVGIIGSCFATWAFIQKNTNHRCVSIYLINLLTADFLLTLALPVKIVVDLGVAPWKLKIFHCQVTACL----IYINMYL
GPR82_               MNNNTTCIQPMISSMALPIIYILLCIVGVFGNTLSQWIFLTKIGKKTSTHIYLSHLVTANLLVCSAMPFMSIYFLKGFQWEYQSAQCRVVNFLGTLSMHASMFV
GPR34_  MTTTSVSSWPYSSHRMRFITNHSDQPPQNFSATPNVTTCPMDEKLLSTVLTTSYSVIFIVGLVGNIIALYVFLGIHRKRNSIQIYLLNVAIADLLLIFCLPFRIMYHINQNKWTLGVILCKVVGTL----FYMNMYI
______            
P2Y12_  SISFLGLITIDRY----------------QKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILT-NRQPRDKNVKKCSFLKSEFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRS-YVRTRGVGK
P2Y13_  GIVLLGLIAFDRF----------------LKIIRPLRNIFLKKPVFAKTVSIFIWFFLFFISLPNMILS-NKEATPSSVKKCASLKGPLGLKWHQMVNNICQFIFWTVFILMLVFYVVIAKKVYDS-YRKSKSKDR
P2Y14_  SIVFFGLISFDRY----------------YKIVKPLWTSFIQSVSYSKLLSVIVWMLMLLLAVPNIILT-NQSVREVTQIKCIELKSELGRKWHKASNYIFVAIFWIVFLLLIVFYTAITKKIFKS-HLKSSRNST
GPR87_  SIVFLGLISIDRY----------------LKVVKPFGDSRMYSITFTKVLSVCVWVIMAVLSLPNIILT-NGQPTEDNIHDCSKLKSPLGVKWHTAVTYVNSCLFVAVLVILIGCYIAISRYIHKS-SRQFISQS-
GPR171_ SIIFLAFVSIDRC----------------LQLTHSCKIYRIQEPGFAKMISTVVWLMVLLIMVPNMMIP-IKDIKEKSNVGCMEFKKEFGRNWHLLTNFICVAIFL-NFSAIILISNCLVIR--QL-YRNKDNENY
GPR82_  SLLILSWIAISRYATLMQKDSSQETTSCYEKIFYGHLLKKFRQPNFARKLCIYIWGVVLGIIIPVTVYYSVIEATEGEESLCYNRQMELGAMISQIAGLIGTTFIGFSFLVVLTSYYSFVSHLRKIRTCTSIMEKD
GPR34_  SIILLGFISLDRY----------------IKINRSIQQRKAITTKQSIYVCCIVWMLALGGFLTMIILT-LKKGG-HNSTMCFHYRDKHNAKGEAIFNFILVVMFWLIFLLIILSYIKIGKNLLRISKRRSKFPNS
        _
P2Y12_  VPRKKVNVKVFIIIAVFFICFVPFHFAR-IPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISMLKCPNATSLSQDNRKKEQDGGDPNEETPM 
P2Y13_  KNNKKLEGKVFVVVAVFFVCFAPFHFAR-VPYTHSQTNNKTDCRLQNQLFIAKETTLFLAATNICMDPLIYIFLCKKFTEKLPCMQGRKTTASSQENHSSQTDNITLG 
P2Y14_  SVKKKSSRNIFSIVFVFFVCFVPYHIAR-IPYTKSQTEAHYSCQSKEILRYMKEFTLLLSAANVCLDPIIYFFLCQPFREILCKKLHIPLKAQNDLDISRIKRGNTTLESTDTL 
GPR87_  SRKRKHNQSIRVVVAVFFTCFLPYHLCR-IPFTFSHLDRLLDESAQKILYYCKEITLFLSACNVCLDPIIYFFMCRSFSRRLFKKSNIRTRSESIRSLQSVRRSEVRIYYDYTDV 
GPR171_ PNVKKALINILLVTTGYIICFVPYHIVR-IPYTLSQTEVITDCSTRISLFKAKEATLLLAVSNLCFDPVLYYHLSKAFRSKVTETFASPKETKAQKEKLRCENNA 
GPR82_  LTYSSVKRHLLVIQILLIVCFLPYSIFKPIFYVLHQRD---NCQQLNYLIETKNILTCLASARSSTDPIIFLLLDKTFKKTLYNLFTKSNSAHMQSYG 
GPR34_  GKYATTARNSFIVLIIFTICFVPYHAFR-FIYISSQLN-VSSCYWKEIVHKTNEIMLVLSSFNSCLDPVMYFLMSSNIRKIMCQLLFRRFQGEPSRSESTSEFKPGYSLHDTSVAVKIQSSSKST 
 ___________TMD1___________               ___________TMD2______         
         ___TMD3____              ____________TMD4____ ________TMD5________
   _____________TMD6________    ________TMD7_______ 
Fig. 3 Conserved residues in P2Y12-like receptors. To identify
conserved group and member-specific positions the amino acid
sequences of P2Y12 (74 orthologs), P2Y13 (31 orthologs), P2Y14 (38
orthologs), GPR87 (51 orthologs), GPR171 (41 orthologs), GPR82
(34 orthologs), and GPR34 (133 orthologs) were aligned using
CLUSTAL W. Residues that are 100% conserved among the
respective orthologs were boxed. Only a few positions are almost
fully conserved among all members of the P2Y12-like group (position
number refers to the relative numbering system by Ballesteros and
Weinstein [73]): TMD1: Phe/Tyr
1.39, Phe
1.57; TMD2: Leu
2.43, Asn/
Asp
2.50, Pro/Ala
2.58; TMD3: Tyr/His
3.33, Arg/Gln
3.50; TMD4: Trp
4.50;
TMD6: Cys/Ser
6.47; Pro
6.50; TMD7: Asp
7.49, Pro
7.50, and the two Cys
residues bridging extracellular loops 1 and 2. The approximate
positions of the seven transmembrane domains (TMD) are given
above the sequences
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key residues that are unique for the P2Y12-like receptor
group and the individual members (Fig. 3). These data sets
were obtained from vertebrate species ranging from
evolutionary old bony and cartilaginous fishes to the more
modern mammals representing 450 Myr of evolution. The
overall identity between P2Y12-like members is rather low
ranging from 19% amino acid identity (human GPR82 vs
human GPR87) to 47% (human P2Y12 and human P2Y13).
Between the respective fish and mammal receptor orthologs
P2Y12 (~49%) shows the highest identity followed by
GPR171 (~48%), GPR34 (~40%), and GPR82 (~35%).
Since not all P2Y12- l i k eG P C Rh a v eo r t h o l o g si na l l
vertebrate classes, we analyzed the structural conservation
within this receptor group by comparing Ka/Ks values
(ratio of the number of nonsynonymous substitutions per
nonsynonymous site and the number of synonymous—or
silent—substitutions per synonymous—or silent—site) of
the P2Y12-like receptor ortholog set from species contain-
ing all group members (Table 3). Although all P2Y12-like
receptors display a purifying selection mode of evolution
(Ka/Ks <<1 indicates high conservation and elimination of
deleterious mutations), there are significant differences
between the members of this receptor group. P2Y12 and
GPR87 were kept most conserved during evolution in
birds and mammals. By contrast, GPR82 appears to be
less constrained as already indicated by a relatively low
conservation at the amino acid level (see above).
As shown in Fig. 3, members of the P2Y12-like group
share only eight fully conserved residues (Phe
1.57, Leu
2.43,
Trp
4.50, Pro
6.50, Asp
7.49, Pro
7.50, and both Cys residues
bridging extracellular loops 1 and 2) when sequences of
more than 400 receptors of this group are compared.
Although the ADP receptors P2Y12 and P2Y13 share more
than 50 fully conserved residues none of these conserved
residues is exclusively found in P2Y12 and P2Y13 but rather
present also in other P2Y12-like receptors (see Fig. 3).
Further, only a few residues are member specifically
conserved (GPR171: Gln
3.53 and Asn
5.59; P2Y13: Met
7.48;
GPR82: Leu
6.44 and Asp
7.57; GPR34: Met
7.52) and have not
been found in other P2Y12-like receptors so far. These facts
suggest that ligand and signaling specificity is determined
by a combination of many, more or less conserved
determinants. It has been proposed that His
6.52/Arg
6.55 and
Lys
7.35/Glu
7.36/Leu
7.39 within TMD6 and the ECL3, re-
spectively, may present such motifs required for nucleotide
binding [38]. However, such residue combination is also
present in some GPR87, GPR171, and GPR34 orthologs
which are not activated by ADP. This does not rule out that
these residues are involved in nucleotide binding of e.g.
P2Y12 but it implicates additional positions which deter-
mine ligand specificity. In-depth structure-function analysis
e.g. by mutagenesis studies are required to identify key
positions and their structural properties.
Physiological relevance of P2Y12-like receptors
Functional characterization of P2Y12-like receptors
in heterologous expression systems
Signal transduction of the ADP receptor P2Y12 via
pertussis toxin-sensitive Gi proteins and adenylyl cyclase
inhibition is well established [22]. Similar Gi protein-
coupling specificity was found for P2Y13 [22, 24], P2Y14
[43], and lyso-PS receptor GPR34 [31, 33]. Because
adenylyl cyclase inhibition assays are usually less sensitive
and robust several other experimental setups were estab-
lished to measure function of P2Y12-like GPCR. It has been
shown that Gα15 and Gα16 can be activated by a wide
variety of GPCR [44]. The ability of Gα16 to bypass the
selectivity of receptor/G protein interaction was also useful
to measure activation of P2Y13 [45]. It has been demon-
strated that replacement of the four or five C-terminal
amino acids of Gαq with the corresponding Gαi residues
(referred to as GΔ6qi4 [46]) confers the ability to stimulate
the PLC-β pathway onto Gi-coupled receptors [47].
Successful heterologous expression and activation by apply-
Table 3 Sequence conservation of P2Y12-like GPCR
Receptor Ka/Ks Pi
(mean ± SD) (mean ± SD)
P2Y12 0.049±0.018 0.145±0.022
P2Y13 0.141±0.070 0.187±0.023
P2Y14 0.103±0.036 0.190±0.024
GPR87 0.046±0.027 0.134±0.018
GPR171 0.078±0.012 0.158±0.021
GPR34 0.082±0.037 0.137±0.026
GPR82 0.202±0.049 0.167±0.034
To compare the sequence conservation of P2Y12-like receptors,
ortholog sequences [relative positions 1.48 (in TMD1) to 7.68 (in C-
term)] from 18 species were aligned and DNA polymorphism analyses
were performed using DnaSP (version 4.1). The Ka/Ks ratio is
calculated from the number of nonsynonymous substitutions per
nonsynonymous site (Ka) and the number of synonymous substitutions
per synonymous site (Ks) for any pair of sequences. The nucleotide
diversity (Pi) is the average number of nucleotide differences per site
between two sequences. The orthologs of the following species were
analyzed because their genome contained all members of the P2Y12-
like group: Bos taurus, Equus caballus, Canis familiaris, Pteropus
vampyrus, Ornithorhynchus anatinus, Monodelphis domestica, Calli-
thrix jacchus, Pan troglodytes, Homo sapiens, Macaca mulatta,
Microcebus murinus, Pongo pygmaeus, Tarsius syrichta, Cavia
porcellus, Mus musculus, Rattus norvegicus, Tursiops truncates,
Gallus gallus
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lyso-PS receptor GPR34 [25, 33, 48].
We have previously shown that P2Y12 as well as the
lyso-PS receptor GPR34 display increased basal activity in
functional assays when compared with other GPCR [33].
This high basal activity can be either discussed as the
natural ground state of the receptor activity equilibrium or
as the effect of receptor agonists that are present in the cell
culture medium or that are released from cells. Analyzing
mutations in the highly conserved DRY motif of P2Y12 we
recently showed that basal activity is abolished in the DHY
mutant but agonist-induced activation remains intact
(Fig. 4). We conclude that the basal activity of the ADP
receptor is rather a genuine property of this receptor and not
due to continuous stimulation by agonists. High basal
activity appears to be a general feature of all members of
the P2Y12-like receptor group. In our initial ortholog screen
we identified two GPR87/P2Y14 receptors, carp GPR87/
P2Y14 types 1a and 1b (AY241103, AY241102), which
differ in only ten amino acid positions. Interestingly, carp
GPR87/P2Y14 type 1b displays higher basal activity and
studies are ongoing to identify residues that promote
constitutive activity.
Because many standard mammalian expression systems
endogenously express P2Y receptors clear-cut functional
studies are difficult to perform. One exception is the
1321N1 human astrocytoma cell line which does not
express P2Y receptors. However, transient expression of
GPCR in 1321N1 cells is limited by low transfection
efficiency and stable transfection of these cells is usually
required. Heterologous expression of GPCR in yeast was
initially established for large-scale purification of receptor
proteins. These advances in the expression of heterologous
GPCR in the yeast Saccharomyces cerevisiae have led to
the development of sensitive and selective assays of ligand-
induced GPCR activation (reviewed in [49]). To facilitate a
more systematic genetic analysis of GPCR function, e.g.,
by saturating random mutagenesis, we took advantage of a
yeast expression system in which parts of the mammalian
GPCR signaling system (GPCR and chimeric G protein) are
linked to a modified yeast pheromone pathway (Fig. 5)
[50]. The coupling of receptor activity to the genetically
engineered yeast pathway allows for rapid and economical
screening of substance libraries and randomly modified
receptor libraries. Functional studies in yeast may have an
advantage especially for P2Y receptors because one can (at
least partially) circumvent specific problems in working
with nucleotide receptors (see above). Only two NTPDases
(GDA1 and YND1/APY1) have been found within the
entire yeast genome which are mainly expressed in the
Golgi apparatus [51]. Although conversion of nucleotides by
nucleotidases and ectoapyrases occur also in yeast and one
cannot exclude conversion of extracellular nucleotides by
yeastenzymes,thereisnoendogenousplasmamembraneP2Y
receptor in yeast which can mediate and, therefore, interfere
with transmembrane signaling of heterologously expressed
Fig. 4 High basal activity is a genuine property of P2Y12. Basal
activity of the wild-type P2Y12 (DRY motif) and a mutant P2Y12
(DHR motif) was determined in transiently transfected COS-7 cells.
Gi coupling of P2Y12 was rerouted to IP production by co-transfection
of a chimeric G protein GΔ6qi4 [46]
Fig. 5 Functional expression and in vitro evolution of GPCR in yeast.
Genetically modified yeast cells are transformed with a mammalian
GPCR. Following agonist activation and constitutive receptor activity,
the receptor couples to a chimeric G protein [backbone yeast G protein
Gpa1 in which the C-terminal five amino acids were replaced by the
respective mammalian G protein sequence (e.g., from the Gi protein)].
Activation of the chimeric G protein enables yeast cells to grow on
histidine-free medium by utilizing parts of the yeast mating pathway
[49]. Gpa yeast ortholog of the mammalian G protein alpha subunit,
Ste4 yeast ortholog of the mammalian G protein beta subunit, Ste18
yeast ortholog of the mammalian G protein gamma subunit, Ste12
transcription factor that is activated by a MAP kinase signaling
cascade, Far1 cell cycle regulator that directly inhibits the yeast
cyclin-dependent kinase Cdc28-Cln
Purinergic Signalling (2007) 3:255–268 263P2Y receptors in yeast. We and others have successfully used
this system for expression and functional study of P2Y12 [52],
P2Y14 [53], and lyso-PS receptor GPR34 (unpublished data).
As shown in Fig. 6a, P2Y12-expressing yeast cells grow only
in the presence of the agonist 2-methylthioadenosine
5′-diphosphate (2MeS-ADP).
Constitutively active GPCR are useful tools in studying
the action of inverse agonists and activation mechanisms in
GPCR. A constitutively active P2Y12 was generated by
replacing the endogenous C terminus with the
corresponding part of the human P2Y1 receptor [54].
Pharmacological evaluation of several P2Y12 antagonists
revealed AR-C78511 (an adenosine derivative) as a potent
P2Y12 inverse agonist. Traditional mutagenesis approaches
are limited to screen for activating mutations because the
number of mutant proteins that can be investigated is
usually relatively small, primarily because of technical
reasons and the time and costs needed to generate and
analyze large numbers of mutant receptors. To circumvent
these limitations, yeast has emerged as a highly useful host
for the in vivo reconstitution of mammalian GPCR.
Therefore, we applied a random mutagenesis and screening
approach in yeast to identify key residues in maintaining
ground stage of the human P2Y12. PCR-based random
mutagenesis was optimized to induce approximately four
mutations in 1 kbp. Several dozen clones were selected and
are now under in-depth investigation. For example, we
identified a triple mutant P2Y12 (Leu
115Gln/Phe
177Ser/
Arg
224Gly), and individual characterization revealed
Leu
115Gln (TMD3) to be mainly responsible for constitu-
tive activity in the yeast expression system (Fig. 6b). These
promising results in applying the yeast expression system
await further efforts to identify functionally relevant
determinants in P2Y12-like receptors.
Establishing in vivo function of P2Y12-like receptors using
mouse models
Selective receptor ligand and receptor-deficient animal
models are suitable tools to evaluate the physiological
relevance of distinct GPCR. Enormous efforts have been
undertaken in the development of selective and clinically
useful ADP and other nucleotide receptor ligands. But
except for P2Y12, dissection of the physiological relevance
of all other P2Y12-like GPCR is at the very early stage.
Since the pharmacological properties of ligands have been
reviewed in detail elsewhere [2] we only shortly summarize
available data on receptor-deficient animal models.
Based on the clinical success of irreversibly bound
P2Y12 antagonists, such as clopidogrel, the pivotal role of
ADP in arterial thrombogenesis is well established. Al-
though the combined action of P2Y1 and P2Y12 is
necessary for the full platelet aggregation response to
ADP, mice deficient for P2Y12 already display reduced
platelet adhesion/activation, thrombus growth, and stability
[18, 55]. Except for the altered platelet functionality P2Y12-
deficient mice appear normal under standard laboratory
conditions. In consent with this finding, we occasionally
identified a frameshift (T insertion at base pair position
667) in the P2Y12 coding sequence of several individuals of
the Asian house mouse (inbred laboratory strain of Mus
musculus castaneus from of the Laboratoire Génome
Populations Interactions Adaptation at the Universite
Montpellier, France) during ortholog screening which
showed no obvious phenotype in standard laboratory
captivity. The platelet function was, however, not tested.
The identified P2Y12 inactivation in some Asian house
mice may reflect either natural polymorphisms present in
the wild population or a new polymorphism that has been
Fig. 6 Functional expression and random mutagenesis of P2Y12 in
yeast. a The human P2Y12 receptor was transformed into modified
yeast (see Fig. 4). The agonist 2-methylthioadenosine 5′-diphosphate
(2MeS-ADP) induces a robust yeast cell growth. b The entire coding
region of the human P2Y12 was subjected to random mutagenesis and
transformed yeast cells were selected for growth in agonist-free U
−/
H
−medium. Colonies that grow under this condition contain a
constitutively active P2Y12. Exemplarily, mutations of a triple mutant
(L
115Q/F
177S/R
224G) were individualized and tested separately for
constitutive activity. The data indicate that L
115Q mainly contributes
to the constitutive activity of the triple mutant
264 Purinergic Signalling (2007) 3:255–268introduced during captivity. To distinguish between these
possibilities, we analyzed the position 667 in P2Y12 from
88 wild M. m. castaneus trapped in Taiwan [41]. All
contained the intact P2Y12 allele indicating that the inactive
P2Y12 allele is very rare or absent in this wild M. m.
castaneus population and favors the hypothesis of its
acquisition in captivity (unpublished observations).
The fact that receptor deficiency is per se compatible
with viability and fertility appears to be true also for other
P2Y12-like receptor-deficient species and mouse models.
For example, mice individually lacking GPR82 and GPR34
are viable, fertile, and produced viable offspring (own
unpublished observation). Further, there are several verte-
brate classes and species naturally deficient in distinct
P2Y12-like receptors. For example, P2Y13 is absent in fish
genomes sequenced so far, GPR82 is not present in
pufferfish genomes, and GPR171 is absent in pufferfish
and Xenopus genomes.
It appears that many functions of P2Y12-like receptors
are more distinct and their disclosure requires specific
challenging conditions. Indeed, P2Y12-deficient mice
revealed an unexpected phenotype when specifically
challenged. CNS injury is accompanied by release of
nucleotides, serving as signals for microglial activation or
chemotaxis. Microglia cells express several purinoceptors,
including P2Y12. Microglia in P2Y12-deficient mice
showed significantly diminished directional branch exten-
sion toward sites of cortical damage in the living mouse.
These results imply that P2Y12 is a primary site at which
nucleotides act to induce microglial chemotaxis at early
stages of the response to local CNS injury [56].
Variants of P2Y12-like receptor genes within human
populations
Activating and inactivating mutations in GPCR have been
made responsible for more than 30 different human
diseases [57]. As expected from its pivotal role in platelet
activation inactivating mutations in P2Y12 can cause a
congenital bleeding disorder. Only a few missense
(Met
1Arg, Pro
258Thr, Arg
256Gln, Arg
265Trp) and frame-
shifting (frameshift at amino acid position 240) mutations
have been reported [19, 58–60]. Unexceptionally, the
missense mutations found are at highly conserved positions
and cause an impairment of receptor function. There are no
other human diseases identified yet which are associated
with dysfunction of P2Y12-like receptors.
The antithrombotic effect of clopidogrel is considerably
variable and the P2Y12 gene was screened for possible
sequence variants. Five nucleotide variations were found in
the human P2Y12 gene, two of them silent substitutions in
the coding region [61]. Several studies were initiated to
investigate the impact of P2Y12 polymorphisms on athero-
sclerosis [62, 63] and clopidogrel efficiency in preventing
neurological events [64] showing no or some association to
one haplotype. In single nucleotide polymorphism (SNP)
projects, such as HapMap [65], SeattleSNP etc., silent
variations have been identified at amino acid position Val
4,
Asn
6, Gly
12, and Phe
182 of P2Y12. For example the C/T
variation at amino acid position Phe
182 is only found in the
African population whereas the G/T variation at position
Gly
12 is present only in European and Asian populations.
One missense mutation (Glu
330Gly; receptor C terminus)
has been detected in SNP projects. This variant is absent in
European and Asian populations but displays an allelic
frequency of about 15% in the African population. The
functional relevance of this missense mutation has not been
studied yet but a Gly at position 330 is naturally found in
many other P2Y12 orthologs including primate P2Y12
almost ruling out a specific input in receptor function.
Onesilentvariant(C/TatIle
59) and one substituting variant
(T/C at Met
158Thr) were identified in the coding region of
P2Y13. The Thr
158 variant is less frequent in African
populations (~4%) when compared to European (~21%) and
Asian (~18%) populations. Met
158 is not conserved and a Thr
at this position is found in the dolphin (Tursiops truncates).
Only two silent substitutions (A/G at Ala
35 and T/C at
Phe
240) have been identified in P2Y14 so far. The GPR171
gene contains two more frequent silent substitutions (T/C at
Tyr
19,A / CT h r
58) and one missense variant (A/G at
Ile
283Val, frequency about 6%) which is located within the
DPXXY motif of TMD7. Ile
283 is quite conserved among
vertebrate GPR171 orthologs. The functional relevance of
Val
283 has not been studied yet but it occurs naturally in the
zebrafish ortholog.
In the human GPR87 gene three silent polymorphisms
(G/A at Pro
46, G/A at Leu
179, C/T at Tyr
355) and one
nonsynonymous polymorphism (C/T at Thr
205Met) are
present. The position 205 is not conserved and Met
205 is
found in several rodents. Only rare silent substitutions in
the coding regions have been found in GPR82 (C/T at
Asp
313) and in GPR34 (A/G at Val
296)[ 34].
SNP stochastically occur in individual genomes and can
amount to a reasonable frequency in populations by drift
but also by selection. There are several approaches and
methods which are suitable to distinguish between drift and
selection. Population genetic models predict that selection
can leave “footprints” in closely linked genomic regions.
Several methods were developed to detect signatures of
selective sweeps in genomic sequences [66]. All methods
require data on allele variation (mainly SNP) within
populations. Large genome-wide analyses have scanned
the human genome for signatures of positive selection on
the basis of nonsynonymous and synonymous substitution
ratios or single nucleotide polymorphism (SNP) data.
Several loci which contain GPCR genes have been
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containing loci showed no strong signatures of recent
positive selection in these studies [67–70].
Conclusion
P2Y12-like receptors which are grouped mainly by phylo-
genetic relations have been an inherent part of the
vertebrate GPCR repertoire since more than 450 Myr.
Although sharing features in respect to structural determi-
nants and signal transduction the activating ligands are
heterogeneous such as nucleotides, nucleotide derivatives,
leukotrienes, and phospholipids. We are at the very
beginning of understanding the physiological importance
of the individual members. The nature of the ligands, first
functional data, and expression of several members in
migrating cells point at functions in immunologic response
and tissue damage response. Doubtless, upcoming receptor-
deficient mouse models and selective receptor ligands will
help to unveil the functions of P2Y12-like receptor members.
Further, one should consider combined receptor-deficient
mouse models within this group but also with other P2Y
receptors to uncover phenotypes which are hidden by
receptor redundancy, e.g., in the case of ADP receptors.
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